MedPath

Omega-3 fatty acids

Generic Name
Omega-3 fatty acids
Brand Names
Animi-3 With Vitamin D, Vitafol-one
Drug Type
Small Molecule
CAS Number
329042-31-1
Unique Ingredient Identifier
71M78END5S

Overview

Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by phytoplankton, a source of diet for fish). Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. Food and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids. Therapeutic products containing omega-3 fatty acid and its derivatives for treatment of hypertriglyceridemia include Lovaza, Omtryg, Epanova, and Vascepa.

Background

Omega-3 fatty acids are polyunsaturated fatty acids (PUFAs) with a double bond at the third carbon atom from the end of the carbon chain. The three types of omega-3 fatty acids involved in human physiology are α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by phytoplankton, a source of diet for fish). Omega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. Food and Drug Administration gave "qualified health claim" status to EPA and DHA omega-3 fatty acids. Therapeutic products containing omega-3 fatty acid and its derivatives for treatment of hypertriglyceridemia include Lovaza, Omtryg, Epanova, and Vascepa.

Indication

Provided as daily supplements. Aa preparation of omega-3-acid ethyl esters is licensed in UK for prevention of recurrent events after myocardial infarction in addition to treatment of hypertriglyceridaemia.

Associated Conditions

No associated conditions information available.

FDA Approved Products

Animi-3
Manufacturer:PBM Pharmaceuticals, Inc
Route:ORAL
Strength:500 mg in 1 1
Approved: 2013/02/06
NDC:66213-543
Reaphirm Plant Source DHA
Manufacturer:Everett Laboratories, Inc.
Route:ORAL
Strength:200 mg in 1 1
Approved: 2011/11/28
NDC:0642-3010
Vitafol One
Manufacturer:Everett Laboratories, Inc.
Route:ORAL
Strength:200 mg in 1 1
Approved: 2021/09/01
NDC:0642-0070

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath